Pathophysiological aspects of frontotemporal dementia -: emphasis on cytoskeleton proteins and autoimmunity

被引:20
作者
Sjögren, M [1 ]
Wallin, A [1 ]
机构
[1] Univ Gothenburg, Sahlgrens Univ Hosp, Psychiat Sect, Inst ClinNeurosci, SE-43180 Molndal, Sweden
关键词
frontotemporal dementia; cerebrospinal fluid; tau; neurofilament protein; gangliosides; sulfatides;
D O I
10.1016/S0047-6374(01)00303-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The aim of this study was to investigate two putative pathophysiological aspects of the common neurodegenerative disorder frontotemporal dementia (FTD). To this end, cerebrospinal fluid (CSF) levels of tau (total tau) and the light subtype of the neurofilament proteins (NFL) were studied in patients with FTD (n = 16) and in age-matched controls (n = 16). In addition, serum was analysed for IgG and IgM antibodies to the most common gangliosides and sulfatide in FTD patients (n = 13) and in age-matched controls (n = 20). The CSF-NFL levels were increased in FTD (1606 +/- 1151 pg/ml, mean +/- S.D.; P < 0.001) compared with controls (308 +/- 203 pg/ml), whereas the CSF-tau levels were normal. In serum, autoantibody IgG-GA1 was significantly increased in FTD (P < 0.05) compared with controls. No correlations were found between the effect parameters and demographic variables in any group. The results of this study suggest that cytoskeleton proteins other than tau are also involved in the pathophysiology of FTD and that autoimmunity may be part of the pathophysiological processes in FTD, as it is believed to be in Alzheimer's disease. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1923 / 1935
页数:13
相关论文
共 58 条
  • [1] Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden -: The Pitea Dementia Project
    Andreasen, N
    Blennow, K
    Sjodin, C
    Winblad, B
    Svärdsudd, K
    [J]. NEUROEPIDEMIOLOGY, 1999, 18 (03) : 144 - 155
  • [2] [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
  • [3] Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
    Arai, H
    Morikawa, Y
    Higuchi, M
    Matsui, T
    Clark, CM
    Miura, M
    Machida, N
    Lee, VMY
    Trojanowski, JQ
    Sasaki, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 262 - 264
  • [4] The tau mutation (val337met) disrupts cytoskeletal networks of microtubules
    Arawaka, S
    Usami, M
    Sahara, N
    Schellenberg, GD
    Lee, G
    Mori, H
    [J]. NEUROREPORT, 1999, 10 (05) : 993 - 997
  • [5] PROTEIN ANALYSES IN CEREBROSPINAL-FLUID .1. INFLUENCE OF CONCENTRATION GRADIENTS FOR PROTEINS ON CEREBROSPINAL-FLUID SERUM-ALBUMIN RATIO
    BLENNOW, K
    FREDMAN, P
    WALLIN, A
    GOTTFRIES, CG
    LANGSTROM, G
    SVENNERHOLM, L
    [J]. EUROPEAN NEUROLOGY, 1993, 33 (02) : 126 - 128
  • [6] tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease?
    Blennow, K
    Wallin, A
    Agren, H
    Spenger, C
    Siegfried, J
    Vanmechelen, E
    [J]. MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) : 231 - 245
  • [7] Breitner JCS, 1996, ANNU REV MED, V47, P401
  • [8] Breitner JCS, 1996, NEUROBIOL AGING, V17, P789
  • [9] BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416
  • [10] FRONTAL-LOBE DEGENERATION OF NON-ALZHEIMER TYPE REVISITED
    BRUN, A
    [J]. DEMENTIA, 1993, 4 (3-4): : 126 - 131